Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Plant Iridoid Glycosides: Biological Properties and Pharmacological Potential].

Created on 05 Jul 2026

Authors

Ewa Młodzińska-Michta, Natalia Gaik

Published in

Postepy biochemii. Volume 72. Issue 2. Pages 143-154. Jun 30, 2026. Epub Jun 30, 2026.

Abstract

Iridoid glycosides are a diverse group of plant secondary metabolites with broad biological activity and promising pharmacological potential. This review summarizes their structural diversity, occurrence in plants, biosynthetic pathways, and biological properties. Particular attention is given to the biosynthesis derived from IPP and DMAPP, including the well-characterized secoiridoid pathway and the less understood pathway leading to compounds such as aucubin and catalpol. The most important biological activities of iridoids, including antibacterial, anti-inflammatory, neuroprotective, gastroprotective, and anticancer effects, are discussed with clear distinction between in vitro studies, animal models, and limited clinical evidence. The review emphasizes that most available data remain preclinical, while clinical studies are still scarce. Major limitations affecting the therapeutic application of iridoids include low bioavailability, variable chemical stability, lack of extract standardization, and difficulties in translating experimental findings into clinical practice.

PMID:
42400425
Bibliographic data and abstract were imported from PubMed on 05 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement